These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22699761)

  • 1. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.
    Antiga E; Volpi W; Cardilicchia E; Maggi L; Filì L; Manuelli C; Parronchi P; Fabbri P; Caproni M
    J Clin Immunol; 2012 Dec; 32(6):1221-32. PubMed ID: 22699761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris.
    Antiga E; Volpi W; Chiarini C; Cardilicchia E; Filì L; Manuelli C; Parrochi P; Fabbri P; Caproni M
    Int J Immunopathol Pharmacol; 2010; 23(3):767-74. PubMed ID: 20943046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acitretin exerted a greater influence on T-helper (Th)1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris.
    Niu X; Cao W; Ma H; Feng J; Li X; Zhang X
    J Dermatol; 2012 Nov; 39(11):916-21. PubMed ID: 22913391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22.
    Hijnen D; Knol EF; Gent YY; Giovannone B; Beijn SJ; Kupper TS; Bruijnzeel-Koomen CA; Clark RA
    J Invest Dermatol; 2013 Apr; 133(4):973-9. PubMed ID: 23223131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial.
    Caproni M; Antiga E; Melani L; Volpi W; Del Bianco E; Fabbri P
    J Clin Immunol; 2009 Mar; 29(2):210-4. PubMed ID: 18763027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response.
    Quaglino P; Bergallo M; Ponti R; Barberio E; Cicchelli S; Buffa E; Comessatti A; Costa C; Terlizzi ME; Astegiano S; Novelli M; Cavallo R; Bernengo MG
    Dermatology; 2011; 223(1):57-67. PubMed ID: 21865674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.
    Zaba LC; Suárez-Fariñas M; Fuentes-Duculan J; Nograles KE; Guttman-Yassky E; Cardinale I; Lowes MA; Krueger JG
    J Allergy Clin Immunol; 2009 Nov; 124(5):1022-10.e1-395. PubMed ID: 19895991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation.
    Johnston A; Fritz Y; Dawes SM; Diaconu D; Al-Attar PM; Guzman AM; Chen CS; Fu W; Gudjonsson JE; McCormick TS; Ward NL
    J Immunol; 2013 Mar; 190(5):2252-62. PubMed ID: 23359500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population.
    Czarnowicki T; Gonzalez J; Shemer A; Malajian D; Xu H; Zheng X; Khattri S; Gilleaudeau P; Sullivan-Whalen M; Suárez-Fariñas M; Krueger JG; Guttman-Yassky E
    J Allergy Clin Immunol; 2015 Jul; 136(1):104-115.e7. PubMed ID: 25748064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
    Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
    BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-α inhibitors reduce the pathological Th
    Campanati A; Orciani M; Lazzarini R; Ganzetti G; Consales V; Sorgentoni G; Di Primio R; Offidani A
    Exp Dermatol; 2017 Apr; 26(4):319-324. PubMed ID: 27376466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis.
    Moy AP; Murali M; Kroshinsky D; Duncan LM; Nazarian RM
    JAMA Dermatol; 2015 Jul; 151(7):753-60. PubMed ID: 25760640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis.
    Lina C; Conghua W; Nan L; Ping Z
    J Clin Immunol; 2011 Aug; 31(4):596-605. PubMed ID: 21562776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis.
    Mashiko S; Mehta H; Bissonnette R; Sarfati M
    J Dermatol Sci; 2017 Nov; 88(2):167-174. PubMed ID: 28743611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept.
    Caldarola G; De Simone C; Carbone A; Tulli A; Amerio P; Feliciani C
    Int J Immunopathol Pharmacol; 2009; 22(4):961-6. PubMed ID: 20074459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
    Wang F; Smith N; Maier L; Xia W; Hammerberg C; Chubb H; Chen C; Riblett M; Johnston A; Gudjonsson JE; Helfrich Y; Kang S; Fisher GJ; Voorhees JJ
    Br J Dermatol; 2012 Jul; 167(1):92-102. PubMed ID: 22458549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased circulating skin-homing cutaneous lymphocyte-associated antigen (CLA)+ type 2 cytokine-producing cells, and decreased CLA+ type 1 cytokine-producing cells in atopic dermatitis.
    Teraki Y; Hotta T; Shiohara T
    Br J Dermatol; 2000 Aug; 143(2):373-8. PubMed ID: 10951148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
    Strober BE; Clarke S
    J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells.
    Nograles KE; Zaba LC; Shemer A; Fuentes-Duculan J; Cardinale I; Kikuchi T; Ramon M; Bergman R; Krueger JG; Guttman-Yassky E
    J Allergy Clin Immunol; 2009 Jun; 123(6):1244-52.e2. PubMed ID: 19439349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P; Del Giglio M; Cotena C; Girolomoni G
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.